Background: Physicians need well-addressed clinical trials assessing benefits and harm of treatments to avoid under-treatment or over-treatment of elderly patients. The main objectives of this report were to present an overview of end points used in clinical trials dedicated to elderly patients; and to assess the evolution in chosen end points before and after the creation of the International Society of Geriatric Oncology in the early 2000s.
Introduction
With the ageing of the population, the importance of detailed oncology data from older populations has become increasingly relevant [1] . Given this demographic shift, medical societies such as the European Organization for Research and Treatment of Cancer (EORTC), the American Society of Clinical Oncology (ASCO) and the International Society for Geriatric Oncology (SIOG) established guidelines on clinical trial methodology in older cancer patients [2] [3] [4] [5] . The need for specific trial designs dedicated to vulnerable or frail older patients was emphasized, as well as the need to increase the number of elderly patients included in clinical trials. Specifically, the need to perform some form of geriatric assessment (GA) and the need to choose appropriate outcome measures were stressed. A recent position paper of the SIOG [5] stated that overall survival (OS) is a crucial end point, but disease-specific survival (DSS) should also be assessed in trials of older cancer patients because of the risk of nononcological deaths resulting from other causes (e.g. other diseases, treatment toxicity) occur much more frequently in the older population. These guidelines also stated that health related quality of life (HRQoL) and preservation of functional capacity and independence were important for understanding more comprehensively the effects of disease and treatment from the patient's perspective [6] .
The SIOG creation and the publication of the first guidelines on geriatric oncology research methods were published in the early 2000s [7] [8] [9] . This date can be seen as the beginning of geriatric oncology as a scientific field. We undertook a review of changes on the use of end points in trials dedicated to elderly patients between the early 2000s and 10 years after as, it takes 10 years from the conception of a study until the publication of its final results.
Methods

Trial selection
In January 2015, two researchers (OLS and JP) identified all reports of clinical trials (phase I, phase II, and phase III trials) assessing therapies for hematological or solid tumors and dedicated to the elderly (at least using a chronological landmark to define the elderly), and all phase III clinical trials among older adults in order to identify subgroup analyses of elderly patients. Included reports were published in English between 1 January 2001 and 31 December 2004 (first time period pre SIOG guidelines), or between 1 January 2011 and 31 December 2014 (second time period after SIOG guidelines) to assess the impact of the SIOG creation in 2000, and the impact of published guidelines on inclusion of elderly patients in oncology trials. A minimum of 10 years is necessary to observe the impact of such guidelines on clinical trials manuscripts frequently published, as several years will pass between writing a protocol and publishing results. The methodology of this systematic review has been published previously [10] . The full Search strategy is reported in supplementary material S1, available at Annals of Oncology online.
Data extraction
Data extraction was performed by the same authors who carried out the initial article selection (OLS and JP). The data were cross-verified by the two data extractors. The collected variables included study design, year of publication, tumor site, source of trial funding, journal impact factor, regions in which trials were conducted, type of investigational therapy, cancer stage, number of enrolled patients, primary age threshold defining elderly patients, proportion of patients in the elderly subgroup, maximum age, median age and end points.
Definition of trial end points
End points were classified as primary and secondary end points. When no clear primary end point was stated by authors, all reported end points were considered as secondary outcomes. When two end points were reported as primary end points or coprimary end points, both end points were considered as primary end points in this review. End points were further classified as OS, composite end point, tumor-centered end points, toxicity end points, patient-reported outcomes (PROs), DSS, impact on functional status end points, feasibility end points, pharmacokinetics or pharmacodynamics end points, and economical end points. Composite end points were defined as time-to-event end points based on a combination of individual events including death and at least one other event related to the tumor evolution (supplementary material S2, available at Annals of Oncology online). Tumor-centered end points included all measure of tumor evolution (including radiological assessment, biological, or histological markers evolution) (supplementary material S2, available at Annals of Oncology online). PROs were defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else [11] . PROs included mainly symptoms and health related QoL assessments. Maintenance of functional status was defined as an end point assessing functioning and (in)dependence through validated instruments [5] . Cognitive function was defined as an end point based on validated cognitive measures [5] . DSS was defined as the time between randomization and the death from cancer. DSS is censored at the time of death from other cause. Clinically meaningful end points were defined as end points showing clinically meaningful benefit for the patient such as assessed by a longer or better life, and ideally both [12] .
Analysis
The nature of end points used in all clinical trials included in this review were described according to their time period of publication. A separate analysis of trial end points was performed for phase II trials and phase III trials, respectively. The evolution of end points used between the two time periods was investigated. For phase II trials, multivariate logistic regression was used to assess the trial characteristics associated with the choice of primary and secondary end points. Odds ratio and their 95% confidence intervals were calculated. All factors of interest and potential confounding factors were included in the multivariate models if they were associated with the choice of end point in univariate analysis (P < 0.10). The added value of each covariate was evaluated using a likelihood ratio test.
Most of the analyses performed were descriptive. Qualitative data were described by percentage and statistical comparisons were performed when appropriate using chi-squared or Fisher exact test. Quantitative data were described by median values and interquartile ranges, and statistical comparisons were performed when appropriate using the Wilcoxon test or the Kruskall-Wallis test.
All analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL) or the R software version 3.3.1 (http://www.R-project.org/).
Results
Characteristics of the selected clinical trials
A total of 1084 clinical trials (supplementary material S3, available at Annals of Oncology online) were included in the analysis: 366 from the first time period (2001) (2002) (2003) (2004) and 718 from the second time period (2011-2014). We identified 263 clinical trials including only elderly patients (or elderly patients along with unfit patients-impaired functional status or comorbidities), over the two time periods: 27 phase I clinical trials, 193 phase II trials and 43 phase III clinical trials. We also identified 280 phase III clinical trials reporting at least one subgroup analysis of elderly patients, and 541 phase III clinical trials reporting no subgroup analysis of elderly patients. Study characteristics of included trials are presented in supplementary Tables S1-S3, available at Annals of Oncology online. Median age of patients included in dedicated phase I trials was 72 years (IQR: 68-76). Median age of patients included in dedicated phase II trials was 72 years (IQR: 72-76), and median age of patients included in dedicated phase III trials was 71 years (IQR: 68-74).
All primary and overall end points in phase I, phase II, and phase III trials are reported in Table 1 . In phase I trials, toxicity was the most frequently reported primary end point (100% and 93% of the cases in the first and second periods, respectively). In phase II trials, the most frequent primary end points were tumorcentered in the first period (46%), and also in the second period (68%). The use of a tumor-centered end point as a primary end point was statistically more frequent in the second time period (68%, P value ¼ 0.0033). This increased use of tumor-centered end point was independent of possible confounders in the multivariate regression model (supplementary Table S4 , available at Annals of Oncology online). Most phase II trials included at least one tumor-centered end point, one toxicity end point, and OS. The use of a composite end point was more frequent in the second time period (66% versus 29%, P value < 0.0001). The use of PROs as secondary end points did not increase over time, and was essentially seen in trials in palliative non-hematologic settings (supplementary Table S5 , available at Annals of Oncology online). All end points (both primary and secondary) used in dedicated phase III trials are reported in Figure 1 . Primary end points used in dedicated phase III trials are reported in Figure 2 . Overall, OS remained the main primary end point (33% and 50%, respectively, in the first and second period, P value ¼ 0.35). Between the first and second period, composite end points became more prevalent as a primary end point (from 7% to 46%, P value ¼ 0.015) while the use of tumor-centered end points decreased (from 40% to 7%, P value ¼ 0.014). The use of PROs as secondary end points increased from 20% in the first time period to 43% in the second time period. Yet, this difference was not statistically significant (P value ¼ 0.19). The use of PROs as primary end point remained low (from 7% to 4%, P value ¼ 1). In these uncommon cases, PROs were never used as a co-primary end point. The evaluation of toxicity also increased slightly from 73% to 86% (P value ¼ 0.42). Feasibility as an end point was uncommon in both time periods (Figure 1) . Cognitive function was never measured in dedicated phase III trials.
In phase III trials with subgroup analyses of elderly patients (Table 1) , the use of composite end points as a primary end point increased from 14% in the first period to 53% in the second period (P value < 0.0001), while the use of OS decreased from 52% to 35% (P value ¼ 0.040). The use of PROs as a primary end Figure 2 . Primary end points used in phase III dedicated clinical trials. OS, overall survival; DSS, disease-specific survival, PK-PD, pharmacokinetic-pharmacodynamic end point. Use of each category of primary end points among 43 phase III clinical trials dedicated to elderly patients. The proportion of trials using each end point category is reported for the first time period (black) and the second time period (grey).
point remained very uncommon but the reporting of PROs as a secondary end point again showed a trend towards being more frequent in the second time period, from 19% to 33% (P value ¼ 0.10). On the contrary, among trials with no subgroup analysis dedicated to elderly patients, the reporting of PROs may even have decreased, between the two time periods (35% and 27%, P value ¼ 0.074). Functional status was infrequently evaluated. This end point was used in 4 phase II trials in the first period (6%), 3 phase II trials in the second period (2%), and 5 phase III trials with a subgroup analysis on elderly patients in the second period (2%). It was never used in dedicated phase III trials. Functional status was never used as a primary end point. Similarly, DSS was used in only 3 out of 263 clinical trials dedicated to elderly patients.
Discussion
We undertook the first comprehensive review of end points used to assess outcomes among elderly in oncology trials. A smaller study limited to breast cancer patients has previously been reported and showed that on nine clinical trials dedicated to elderly patients, only five included any patient-related end point (56%, P¼ 0.02) [13] . Another study focusing on hematological malignancies has shown that patient-centered outcomes such as QoL, health care utilization, and functional capacity were only incorporated in a small number of trials (<10%). Even in trials dedicated to older patients, the primary focus lied on standard tumor-centered outcomes, while patient-centered outcomes were included in less than one-fifth of studies [14] . Our study found that tumor-centered outcomes and OS were the first and second most common primary end points used in dedicated phase III trials during the first time period. Interestingly, during the second time period, OS was the most common primary end point used, whereas composite end points became the second most common primary end point, while tumor-centered end points were hardly used at all. This might be explained by the fact that composite end points are considered as surrogate end points for OS in many cancer types and became more frequently used as a primary end point as it can accelerate the achievement of significant results and therefore new drug approvals [15, 16] .
Perhaps more importantly, our study identified some glaring deficits in the end points used in these studies. DSS is considered to be an important data to help interpret OS data in this population with high competing risks of death from non-oncology comorbidities [17] [18] [19] even though DSS is limited by the fact that determining cause of death is extremely challenging in older patients. In DSS, deaths not related to the malignant disease are censored. As a consequence, this end point reflects directly the treatment antitumoral effect on survival, and does not take into account toxic death or death related to comorbidities. Yet, DSS was not used as a primary end point in any of the included studies. In contrast, PROs were reported for many (43%) trials. These results are in accordance with the results reported by de Glas et al. [13] who showed that 56% of breast older cancer patients trials incorporated at least one patientrelated end point. PROs like HRQoL are a major concern for cancer patients, and it can be affected by symptoms caused by cancer, as well as by treatment-induced toxicity [20] . PROs may then be especially important for elderly patients. For example, elderly patients are less willing to compromise their HRQoL for a potential survival gain [21] . In a similar way, functional status should be one of the major principles of cancer management in the elderly since a negative impact on patient's functional capacity will have a negative impact on survival as well [22] . The prolongation of 'active' life expectancy seems much more important than the prolongation of life expectancy as such. The use of PROs might have been limited by some methodological concerns such as definition of functional dependence, optimal cut-off, and the fact that other handicaps can interfere with functionality while it might not have real impact on QoL [3] .
Our study has some limitations. It is a retrospective systematic review of published trials. Therefore, we did not take into account publication bias [23] , which can be significant, especially in elderly patients with comorbidities or impaired functional status. Indeed, due to increased toxicity and decreased tolerance [24] , authors and sponsors (such as industry [25] ) may be reluctant to publish trial reports with negative results and editors might be less likely to accept it [26] . A second limitation is that we did not look at physiological age, such as assessed with a comprehensive GA, and limited our analyses to chronological age. A third and last limitation is that it takes many years from protocol writing to publication of results. As a consequence, the full effect of SIOG, EORTC and ASCO's guidelines may not have been reached in our second time period. However, the sample size, the robustness and the importance of the results are enough not to ignore the conclusions drawn.
When designing a clinical trial, the choice of primary and secondary end point is often challenging, as all end points have limits. This challenge is true among young and fit patients, but is even more important among elderly and frail patients. First we recommend that authors include systematically functional status, and PROs when designing a trial among elderly patients. For phase III confirmatory trial, DSS should be considered as the disease-specific cause of death is believed to be recognized with enough accuracy. Moreover, a universal GA data set should be required for clinical trials. This GA should at least include a validated evaluation of functional status [27] which add information compared to Eastern Cooperative Oncology Group performance status in elderly cancer patients [28] , an objective evaluation of comorbidities, cognitive function, depression, and nutrition in order to stratify analyses on different subgroups of older patients (vulnerable and frail). This is mandatory in order to extrapolate data in clinical practice. Elderly patients should not be excluded from non-dedicated clinical trials in order to have a minimum cohort of elderly representative of demographic data. We also recommend new trials focusing on geriatric interventions.
To conclude, we showed that OS remains the dominant end point in trials including elderly oncology patients, as it is in oncology trials more generally. Yet, the number of clinical trials dedicated to elderly patients remained low. Given the specificities of elderly patients-high competing risk of non-oncological death; importance of QOL; and importance of independencewe believe that other end points deserve special attention. In particular, a focus on DSS, PROs and functional status would be relevant.
